

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-91. (Canceled)

92. (Currently Amended) A method for stimulating a T cell response to a tumor cell in a subject with a tumor, comprising modifying the tumor cell to express ~~a CD2 ligand~~ CD59 and a CD28 or CTLA4 ligand, wherein said CD28 or CTLA4 ligand is selected from the group consisting of B7-1, B7-2, and combinations thereof, such that stimulation of a T cell response to a tumor cell occurs.

93. (Currently Amended) The ~~A~~ method of claim 92, wherein the tumor cell is modified to express ~~a CD2 ligand~~ CD59 and a CD28 or CTLA4 ligand by introducing into the tumor cell at least one nucleic acid encoding ~~the CD2 ligand~~ CD59 and the CD28 or CTLA4 ligand in a form suitable for expression of ~~the CD2 ligand~~ CD59 and the CD28 or CTLA4 ligand on the tumor cell surface.

94. (Currently Amended) The ~~A~~ method of claim 93, wherein the tumor cell is obtained from the subject and modified *ex vivo* to form a modified tumor cell and the method further comprises administering the modified tumor cell to the subject.

95. (Currently Amended) The ~~A~~ method of claim 93, wherein a first sample of tumor cells is modified to express ~~a CD2 ligand~~ CD59 to form a first sample of modified tumor cells

and a second sample of tumor cells is modified to express a CD28 or CTLA4 ligand to form a second sample of modified tumor cells

96. (Currently Amended) The A method of claim 95, wherein the first and second samples of modified tumor cells are administered to the subject simultaneously.

97. (Currently Amended) The A method of claim 93, wherein the first and second samples of modified tumor cells are administered to the subject sequentially.

98. (Currently Amended) A The method of claim 92, further comprising contacting T cells of the subject with an agent that stimulates exposure of a T11.3 neo-epitope on a CD2 surface receptor on the T cell.

99. (Currently Amended) A The method of claim 98, wherein the agent is IL-2 or IL-4.

100. (Currently Amended) A The method of claim 99, wherein T cells are obtained from the subject and contacted with IL-2 or IL-4 *ex vivo* and the method further comprises readministering the T cells to the subject.

101. (Cancel)

102. (Previously Presented) The method of claim 92, wherein said CD28 or CTLA4 ligand is B7-1.

103. (Previously Presented) The method of claim 92, wherein said CD28 or CTLA4 ligand is B7-2.

104.-107. (Cancel)